A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and ...

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and ...

Initiation of GLP-1 drugs was associated with a 14% lower risk of developing new substance use disorders compared with SGLT2 inhibitors in veterans. Veterans with pre-existing substance use disorders ...

By Hugo Francisco de Souza A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for ...

Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels. Further research led to the creation of a stabilized GLP-1RA called semaglutide, the active ...

GLP-1 agonist drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide are set to become all-time best-selling drugs. Structure Therapeutics has entered the race with an oral GLP-1 candidate, ...

Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity may also help to lower the risk of addiction to a range of substances including alcohol, cannabis, cocaine, ...

A large study of US veterans suggests that diabetes and weight-loss medicines may curb cravings and lower severe addiction outcomes, though clinical trials are still needed.

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...